Medico Remedies Ltd Upgraded to Hold as Valuation and Financials Improve

Valuation Upgrade: From Fair to Attractive

The most significant catalyst behind the rating upgrade is the change in Medico Remedies’ valuation grade, which has moved from fair to attractive. The company currently trades at a price-to-earnings (PE) ratio of 24.14, which, while slightly higher than some peers like Bliss GVS Pharma (20.92), remains reasonable given its growth prospects. The price-to-book value stands at 4.19, and the enterprise value to EBITDA ratio is 17.57, indicating a valuation discount relative to more expensive peers such as Shukra Pharma and NGL Fine Chem, which trade at EV/EBITDA multiples of 39.37 and 23.47 respectively.

Moreover, Medico Remedies’ PEG ratio of 0.78 suggests undervaluation relative to its earnings growth, a key factor in the upgrade. This compares favourably with peers like Bliss GVS Pharma (0.87) and Kwality Pharma (0.39), positioning Medico Remedies as an attractive option for investors seeking value in the pharmaceuticals sector.

Financial Trend: Consistent Growth Amidst Market Challenges

Financially, Medico Remedies has demonstrated positive momentum, with the latest half-year profit after tax (PAT) at ₹5.44 crores growing by 30.46%. The company’s profit before tax excluding other income (PBT less OI) for the quarter reached ₹3.15 crores, marking a robust 52.17% increase. This consistent quarterly performance over the last four quarters underpins the improved financial trend assessment.

Return on capital employed (ROCE) has been a standout metric, with the latest figure at 15.85% and the half-year ROCE peaking at 20.65%. This indicates efficient capital utilisation and strong management effectiveness. Additionally, the company maintains a low debt-to-EBITDA ratio of 0.89 times, signalling a healthy ability to service debt and maintain financial stability.

Quality Assessment: High Management Efficiency and Operational Strength

Medico Remedies’ quality grade remains solid, supported by its high ROCE and return on equity (ROE) of 17.35%. The company’s operational efficiency and management effectiveness have been key contributors to its improved standing. Despite being a micro-cap stock, it has delivered consistent earnings growth and maintained a disciplined capital structure, which is critical in the capital-intensive pharmaceuticals industry.

However, the company’s stock price has underperformed relative to the benchmark indices. Over the past year, Medico Remedies has generated a negative return of -25.74%, compared to the Sensex’s -5.18%. Over three years, the underperformance is even more pronounced, with the stock declining by 57.65% while the Sensex gained 27.63%. This disparity highlights the market’s cautious stance despite the company’s improving fundamentals.

Technicals: Cautious Outlook Amid Price Volatility

From a technical perspective, Medico Remedies’ stock price has shown volatility, with a day change of -6.30% on 30 March 2026, closing at ₹33.75 after opening near ₹36.03. The 52-week high stands at ₹62.00, while the low is ₹32.11, indicating a wide trading range and recent weakness. The stock’s downward trend over the past year and three years, with returns of -25.74% and -57.65% respectively, suggests that technical momentum remains subdued despite improving fundamentals.

Investors should note that the stock is currently trading near its 52-week low, which may offer a potential entry point for those focusing on valuation and financial strength rather than short-term price action. However, the persistent underperformance relative to the broader market and sector peers warrants a cautious stance.

Comparative Industry Positioning

Within the Pharmaceuticals & Biotechnology sector, Medico Remedies is classified as a micro-cap company with a Mojo Score of 50.0 and a Mojo Grade upgraded to Hold from Sell. This contrasts with some peers that remain fairly or very expensive, such as Shukra Pharma and NGL Fine Chem. The company’s valuation metrics, particularly EV to capital employed at 3.75, are attractive compared to sector averages, reinforcing the rationale for the upgrade.

Despite the positive financial trajectory, the stock’s historical underperformance against the Sensex and BSE500 indices over multiple periods highlights the challenges faced by smaller pharmaceutical companies in gaining investor confidence amid competitive pressures and market volatility.

Outlook and Investor Considerations

Medico Remedies’ upgrade to a Hold rating reflects a balanced view of its current position. The company’s attractive valuation, improving financial metrics, and strong management efficiency provide a solid foundation for potential recovery. However, the stock’s recent price underperformance and technical weakness suggest that investors should approach with measured expectations.

Long-term investors may find value in the company’s consistent earnings growth, low leverage, and operational discipline, especially given the pharmaceutical sector’s growth potential. The PEG ratio below 1.0 and ROCE above 15% are encouraging signs that the company is generating returns above its cost of capital, which could translate into shareholder value over time.

Nevertheless, the micro-cap status and historical volatility mean that risk remains elevated compared to larger, more established peers. Investors should weigh these factors carefully and consider portfolio diversification strategies.

Summary of Key Metrics

• PE Ratio: 24.14 (attractive valuation)
• Price to Book Value: 4.19
• EV to EBITDA: 17.57
• PEG Ratio: 0.78
• ROCE (Latest): 15.85%
• ROE (Latest): 17.35%
• Debt to EBITDA: 0.89 times
• PAT Growth (Latest 6 months): 30.46%
• PBT less OI Growth (Quarterly): 52.17%
• Market Cap Grade: Micro-cap
• Mojo Score: 50.0 (Hold, upgraded from Sell)

In conclusion, Medico Remedies Ltd’s investment rating upgrade to Hold is justified by its improved valuation and financial performance, despite ongoing challenges in price momentum and market sentiment. Investors should monitor quarterly results and sector developments closely to reassess the stock’s potential as it navigates a competitive and evolving pharmaceuticals landscape.

Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Start Today